{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:34:46Z","timestamp":1785908086567,"version":"3.56.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007613","name":"Ankara University","doi-asserted-by":"publisher","award":["BAP-20L0237002"],"award-info":[{"award-number":["BAP-20L0237002"]}],"id":[{"id":"10.13039\/100007613","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.bioorg.2025.108345","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T11:50:58Z","timestamp":1741175458000},"page":"108345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of novel amidoxime or amidine analogues of some 4-anilino-6,7-dimethoxyquinazolines with a potent EGFR inhibitory effect"],"prefix":"10.1016","volume":"158","author":[{"given":"Cemre","family":"Acar Hal\u0131c\u0131","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"G\u00f6ker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zg\u00fcr","family":"K\u00fct\u00fck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130smail","family":"\u00c7elik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunca G\u00fcl","family":"Altunta\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.108345_bb0005","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12943-024-02069-w","article-title":"Cancer, metastasis, and the epigenome","volume":"23","author":"Kiri","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2025.108345_bb0010","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrd773","article-title":"Protein kinases-the major drug targets of the twenty-first century?","volume":"1","author":"Cohen","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.108345_bb0015","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0163-7258(98)00045-X","article-title":"The epidermal growth factor receptor and its inhibition in cancer therapy","volume":"82","author":"Woodburn","year":"1999","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2025.108345_bb0020","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/1040-8428(94)00144-I","article-title":"Epidermal growth factor-related peptides and their receptors in human malignancies","volume":"19","author":"Salomon","year":"1995","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bioorg.2025.108345_bb0025","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ejmech.2017.07.005","article-title":"Development of a series of novel 4-anilinoquinazoline derivatives possessing quinazoline skeleton: design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro","volume":"138","author":"Chang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108345_bb0030","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1126\/science.8066447","article-title":"A specific inhibitor of the epidermal growth factor receptor tyrosine kinase","volume":"265","author":"Fry","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2025.108345_bb0035","first-page":"47","article-title":"Hedefe y\u00f6nelik kanser tedavisinde kullan\u0131lan ak\u0131ll\u0131 ila\u00e7lar: EGFR inhibit\u00f6rleri","volume":"44","author":"Acar","year":"2019","journal-title":"FABAD J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2025.108345_bb0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.fjps.2016.02.001","article-title":"Recent advances in 4-aminoquinazoline based scaffold derivatives targeting EGFR kinases as anticancer agents","volume":"2","author":"Ismail","year":"2016","journal-title":"Future J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2025.108345_bb0045","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/j.cllc.2019.12.003","article-title":"Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non\u2013small-cell lung cancer: a clash of the generations","volume":"21","author":"Shah","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.bioorg.2025.108345_bb0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics","volume":"71","author":"Siegel","year":"2021","journal-title":"Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2025.108345_bb0055","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.semcancer.2014.05.002","article-title":"Targeting apoptosis for anticancer therapy","volume":"31","author":"Fulda","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bioorg.2025.108345_bb0060","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1371\/journal.pmed.0040316","article-title":"Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics","volume":"4","author":"Cragg","year":"2007","journal-title":"PLoS Med."},{"key":"10.1016\/j.bioorg.2025.108345_bb0065","doi-asserted-by":"crossref","first-page":"11867","DOI":"10.1158\/0008-5472.CAN-07-1961","article-title":"Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion","volume":"67","author":"Deng","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108345_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040294","article-title":"Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas","volume":"4","author":"Gong","year":"2007","journal-title":"PLoS Med."},{"key":"10.1016\/j.bioorg.2025.108345_bb0075","doi-asserted-by":"crossref","first-page":"19503","DOI":"10.1073\/pnas.0905056106","article-title":"Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition","volume":"106","author":"Faber","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioorg.2025.108345_bb0080","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1158\/1078-0432.CCR-17-1574","article-title":"Overcoming acquired resistance to AZD9291, a third-generation EGFR inhibitor, through modulation of MEK\/ERK-dependent Bim and mcl-1 degradation","volume":"23","author":"Shi","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108345_bb0085","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.1158\/0008-5472.CAN-10-2668","article-title":"MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents","volume":"71","author":"Fan","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108345_bb0090","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1158\/1078-0432.CCR-18-0304","article-title":"Increased synthesis of MCL-1 protein underlies initial survival of EGFR-mutant lung cancer to EGFR inhibitors and provides a novel drug target","volume":"24","author":"Song","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108345_bb0095","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/onc.2009.198","article-title":"Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors","volume":"28","author":"Gazdar","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2025.108345_bb0100","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ccr.2006.12.017","article-title":"Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity","volume":"11","author":"Yun","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2025.108345_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103811","article-title":"A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy","volume":"99","author":"Ayati","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108345_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112640","article-title":"Novel quinazoline-based EGFR kinase inhibitors: a review focussing on SAR and molecular docking studies (2015-2019)","volume":"204","author":"Bhatia","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108345_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114856","article-title":"Discovery and optimization of 4-anilinoquinazoline derivatives spanning ATP binding site and allosteric site as effective EGFR-C797S inhibitors","volume":"244","author":"Dou","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108345_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116858","article-title":"Design, synthesis, and biological evaluation of diphenyl ether substituted quinazolin-4-amine derivatives as potent EGFRL858R\/T790M\/C797S inhibitors","volume":"279","author":"Dou","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108345_bb0125","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.ejmech.2008.10.003","article-title":"Synthesis and antiparasitic and antifungal evaluation of 2\u2032-arylsubstituted-1H, 1\u2032 H-[2, 5\u2032] bisbenzimidazolyl-5-carboxamidines","volume":"44","author":"Alp","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108345_bb0130","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1016\/j.bmc.2016.06.047","article-title":"Synthesis and potent antiprotozoal activity of mono\/di amidino 2-anilinobenzimidazoles versus plasmodium falciparum and Trypanosoma brucei rhodesiense","volume":"24","author":"Karaaslan","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108345_bb0135","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s12272-014-0438-x","article-title":"Synthesis and anticancer effects of some novel 2-(4-phenoxyphenyl)-1H-benzimidazole derivatives on K562 cell line","volume":"38","author":"Gurkan-Alp","year":"2014","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.bioorg.2025.108345_bb0140","series-title":"Comprehensive Organic Functional Group Transformations","first-page":"s. 741-782","article-title":"5.19-Amidines and N-substituted Amidines, a.R","author":"Dunn","year":"1995"},{"key":"10.1016\/j.bioorg.2025.108345_bb0145","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ejmech.2019.04.012","article-title":"Design, synthesis and docking studies of benzimidazole derivatives as potential EGFR inhibitors","volume":"173","author":"Celik","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108345_bb0150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioorg.2025.108345_bb0155","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108345_bb0165","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/cmdc.201600182","article-title":"A boiled-egg to predict gastrointestinal absorption and brain penetration of small molecules","volume":"11","author":"Daina","year":"2016","journal-title":"Chem. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108345_bb0170","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.108345_bb0175","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1021\/jm9503613","article-title":"Tyrosine kinase inhibitors. 8. An unusually steep structure- activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor","volume":"39","author":"Bridges","year":"1996","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108345_bb0180","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1021\/jm0506423","article-title":"Identification of potent and selective inhibitors of PDGF receptor autophosphorylation","volume":"49","author":"Furuta","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108345_bb0185","series-title":"U.S. patent application no. 12\/300,751","author":"Boyer","year":"2009"},{"key":"10.1016\/j.bioorg.2025.108345_bb0190","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.bmc.2010.11.057","article-title":"Virtual screening and synthesis of quinazolines as novel JAK2 inhibitors","volume":"19","author":"Yang","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108345_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2021.106028","article-title":"Kinome-wide RNAi screening for mediators of ABT-199 resistance in breast cancer cells identifies Wee1 as a novel therapeutic target","volume":"137","author":"Aka","year":"2021","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.bioorg.2025.108345_bb0200","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/sj.embor.7400375","article-title":"Proapoptotic BAX and BAK control multiple initiator caspases","volume":"6","author":"Ruiz-Vela","year":"2005","journal-title":"EMBO Rep."},{"key":"10.1016\/j.bioorg.2025.108345_bb0205","doi-asserted-by":"crossref","first-page":"31313","DOI":"10.18632\/oncotarget.5182","article-title":"Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC cells","volume":"6","author":"Wu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2025.108345_bb0210","doi-asserted-by":"crossref","first-page":"46265","DOI":"10.1074\/jbc.M207135200","article-title":"Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor","volume":"277","author":"Stamos","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.108345_bb0215","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1021\/ml300327z","article-title":"Structure-based approach for the discovery of pyrrolo [3, 2-d] pyrimidine-based EGFR T790M\/L858R mutant inhibitors","volume":"4","author":"Sogabe","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108345_bb0220","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007205","article-title":"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer","volume":"5","author":"Yasuda","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioorg.2025.108345_bb0225","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1038\/s41467-022-34398-z","article-title":"Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations","volume":"13","author":"van Alderwerelt","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.108345_bb0230","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1021\/acs.jctc.1c00302","article-title":"OPLS4: improving force field accuracy on challenging regimes of chemical space","volume":"17","author":"Lu","year":"2021","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.bioorg.2025.108345_bb0235","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108345_bb0240","doi-asserted-by":"crossref","first-page":"W530","DOI":"10.1093\/nar\/gkab294","article-title":"PLIP 2021: Expanding the scope of the protein\u2013ligand interaction profiler to DNA and RNA","volume":"49","author":"Adasme","year":"2021","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108345_bb0245","doi-asserted-by":"crossref","DOI":"10.1063\/5.0012280","article-title":"CHARMM-GUI supports the Amber force fields","volume":"153","author":"Lee","year":"2020","journal-title":"J. Chem. Phys."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108345_bb0250","doi-asserted-by":"crossref","first-page":"641a","DOI":"10.1016\/j.bpj.2015.11.3431","article-title":"CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM\/OpenMM simulations using the CHARMM36 additive force field","volume":"110","author":"Lee","year":"2016","journal-title":"Biophys. J."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825002251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825002251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T18:30:17Z","timestamp":1765218617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825002251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":49,"alternative-id":["S0045206825002251"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108345","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of novel amidoxime or amidine analogues of some 4-anilino-6,7-dimethoxyquinazolines with a potent EGFR inhibitory effect","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108345","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108345"}}